- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02650076
A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects
April 10, 2016 updated by: Sanwa Kagaku Kenkyusho Co., Ltd.
The primary objective is to confirm the target receptor occupancy of SK-1405 and to correlate receptor occupancy with SK-1405 dose and plasma concentration.
The secondary objective is to assess the safety and tolerability of SK-1405 in healthy, Caucasian, male subjects.
Study Overview
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom
- Hammersmith Medicines Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Able and willing to provide written informed consent to participate in this study, as confirmed by signing the informed consent document(s).
- Adult Caucasian male aged ≥20 and ≤50 years.
- Body Mass Index (BMI) of ≥ 20 and ≤ 30 kg/m2.
- Height ≤ 190 cm.
- Subject is a non-smoker or has not smoked in the past 6 months.
- Subject is considered to be in good health in the opinion of the investigator.
- Subject's pre-study clinical laboratory findings are within normal range.
- Subject must be willing and able to comply with all protocol requirements.
Exclusion Criteria:
- Use of prohibited medications as described in the study protocol.
- Current known or suspected history of drug/solvent abuse.
- Current known or suspected history of alcohol abuse or currently drinks in excess of 21 units per week.
- Subjects who have consumed caffeine containing products within 24 hours prior to baseline PET-CT.
- Any concurrent medical, surgical, or psychiatric condition that may affect the subject's ability to meet all protocol requirements during the study duration and/or any significant illness in the investigator's opinion in the 4 weeks before screening.
- Participation in any other clinical study with an investigational drug/device within three months prior to the first day of dosing and after enrolment in the current study.
- Subject has a positive result of HIV screen, hepatitis B screen or hepatitis C screen.
- Subject has had a serious adverse reaction or significant hypersensitivity to any drug.
- Subject has donated 500 mL or more of blood within the three months prior to screening.
- History of neurological conditions.
- Participation in a research study or other radiation exposure which in conjunction with this study would result in additional ionisation radiation exposure exceeding 10 mSv within the last year.
- A contraindication for MRI, including but not limited to, MRI-incompatible pacemakers, recent metallic implants, foreign body in the eye, or other indications as assessed by a standard pre-MRI questionnaire, that preclude the subject undergoing MRI scans.
- Subject has claustrophobia.
- Subjects who have consumed Saint John's wort, red wine, Seville oranges, grapefruit or grapefruit juice within 7 days prior to dosing.
- Subject has a partner who is either pregnant or breastfeeding for the duration of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The receptor occupancy of SK-1405 as measured by PET-CT imaging with [11C]-carfentanil
Time Frame: up to 4 days
|
up to 4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2016
Primary Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
January 5, 2016
First Submitted That Met QC Criteria
January 6, 2016
First Posted (Estimate)
January 8, 2016
Study Record Updates
Last Update Posted (Estimate)
April 12, 2016
Last Update Submitted That Met QC Criteria
April 10, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MO001A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pruritus
-
Kissei Pharmaceutical Co., Ltd.Completed
-
Toray Industries, IncCompletedUremic PruritusBulgaria, Germany
-
Cara Therapeutics, Inc.CompletedPruritus | Uremic PruritusUnited States
-
Qilu Pharmaceutical (Hainan) Co., Ltd.Recruiting
-
Thammasat University HospitalCompletedUremic PruritusThailand
-
Conmed Pharmaceutical & Bio-Medical CorporationChang Gung Memorial Hospital; Kaohsiung Medical University; Tri-Service General... and other collaboratorsCompleted
-
Haisco Pharmaceutical Group Co., Ltd.Completed
-
Kissei Pharmaceutical Co., Ltd.Maruishi PharmaceuticalCompleted
-
Chang Gung Memorial HospitalUnknown
-
Lumosa Therapeutics Co., Ltd.Unknown
Clinical Trials on SK-1405
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedUremic Pruritus in Hemodialysis PatientsJapan
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Molecular Insight Pharmaceuticals, Inc.CompletedProstate CancerUnited States
-
ModernaTX, Inc.Active, not recruitingNorovirus Acute GastroenteritisUnited States
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Kowa Research Institute, Inc.CompletedType 2 Diabetes MellitusUnited States
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
SK Chemicals Co., Ltd.CompletedErosive GastritisKorea, Republic of